Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials - Wikidata - wikimedia - TriplyDB

Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials

Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials

http://www.wikidata.org/entity/Q57569239

about

Current stage in inflammatory bowel disease: What is next?Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases Pharmacogenetics in inflammatory bowel disease Associations between NOD2/CARD15 genotype and phenotype in Crohn's disease--Are we there yet?Review article: maintenance treatment of Crohn's disease.Predicting response to Anti-TNF Agents for the treatment of crohn's disease.Review article: the expanding role of biological agents in the treatment of inflammatory bowel disease - focus on selective adhesion molecule inhibition.Pharmacogenetics and inflammatory bowel disease: progress and prospects.Mechanisms of infliximab: the reverse side of a drug effect.Novel biological strategies in inflammatory bowel diseases.The role of pharmacogenomics in the prediction of efficacy of anti-TNF therapy in patients with Crohn's disease.NOD2 polymorphism predicts response to treatment in Crohn's disease--first steps to a personalized therapy.Review article: exploration of the genetic aetiology of inflammatory bowel disease--implications for diagnosis and therapy.Current status of genetics research in inflammatory bowel disease.Protein therapeutics: new applications for pharmacogenetics.Genetic variants and the risk of Crohn's disease: what does it mean for future disease management?Review article: genetic susceptibility and application of genetic testing in clinical management of inflammatory bowel disease.Clinical application of pharmacogenetics in gastrointestinal diseases.Recent understanding of IBD pathogenesis: implications for future therapies.Review article: interactions between genotype and response to therapy in inflammatory bowel diseases.Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases.How does genotype influence disease phenotype in inflammatory bowel disease?Pharmacogenetics of Crohn's disease.Pharmacogenomics in the treatment of inflammatory bowel disease.Genetic dissection of inflammatory bowel disease: unravelling etiology and improving diagnostics.Genetic and genomic predictors of anti-TNF response.The role of pharmacogenetics in nonmalignant gastrointestinal diseases.Current advantages in the application of proteomics in inflammatory bowel disease.Current relevance of pharmacogenetics in immunomodulation treatment for Crohn's disease.Personalizing therapy for inflammatory bowel diseases.The use of prognostic factors in inflammatory bowel diseases.Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management.Impact of NOD2/CARD15 polymorphisms on response to monoclonal antibody therapy in Crohn's disease: a systematic review and meta-analysis.Pharmacogenetic biomarkers of response in Crohn's disease.Differential expression and regulation of ADAM17 and TIMP3 in acute inflamed intestinal epithelia.Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors.Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease.Can We Predict the Efficacy of Anti-TNF-α Agents?NOD2 and bacterial recognition as therapeutic targets for Crohn's disease.Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis.

P2860

Q26777429-7A433F77-CFB6-40F5-971B-15A33164DCC1 Q28072105-656E129B-0729-4FEC-823D-F3DA6A5852BC Q28246002-49AD754F-5269-457E-B064-BFCAE8A0F238 Q28276011-EBC20DD3-58D6-4DE4-B875-4DE93AE7CBBB Q33966376-433B2E8B-F0B4-44AC-A206-EE9988283889 Q34408990-13961251-07A3-4306-8F2E-00D48DA8C136 Q35161097-1E42FF0A-EC56-457E-AB40-17FF701B3769 Q35787609-6C811252-2955-4693-A3A6-6F5EE37F88E3 Q35787649-C8C1F30D-9DF6-45FA-A560-88351FDD8C4B Q35787653-CD3177A6-C237-49E0-AA03-084E0A6BA4CE Q35814374-4C4550A9-25ED-4218-8EF2-03E3097963A5 Q35837384-D1D98C15-3DE8-49E8-A2EF-2B2EF686C3DD Q35880358-20023A1A-DD39-4A6F-98DF-55C6005FC64A Q36233839-AE3D570F-0569-454C-815A-A6FD727359AD Q36501235-4404E5CB-468B-471D-A237-712BD9767B9F Q36548717-C0CA01C4-9747-4D64-9086-61A5BE0657BE Q36589391-6E1BF58A-EB58-4EA7-958C-A6A850925B48 Q36613862-494743C2-93DA-4F3F-9DCF-926FBDA38C6D Q36639759-94F0E637-38C7-44D6-A9EB-BE0BC56D36A2 Q36642796-6D6C24A7-4F9A-4DA7-9652-7B8528C7663B Q36897403-4449A44E-C7DE-4D12-9D5A-BC828D3524C9 Q37038666-6F21A792-3DBC-4627-B116-91EC6682A426 Q37205946-C98F7B9B-B828-4777-B283-1FB8C98CA42D Q37710516-E9D58419-01D3-424A-AE91-3F8075F0BB2B Q37755229-04E247FB-54B8-45E9-BD51-B67D4A1F1511 Q37951648-0BD937C3-5D7E-424E-8D5B-36D6570A7999 Q37981892-A8FB5D2A-12D3-4B73-A3BC-1CB95289C39E Q38022190-DD6FF3F0-B55E-456A-A666-CD951CCD8386 Q38022258-9E2B4B56-238C-4FB4-BB87-BFD6EFE98349 Q38132279-A8EC4256-D41E-441A-B3A3-BCBCED65537F Q38254878-557AD676-6333-48F6-BE11-52DBF2F964B6 Q38619950-EF3CD2CA-F9D1-4EB3-92D4-ACDD26FA450F Q38929952-A1647EB2-9DFD-4473-830D-EEE17D314F21 Q39385446-0FE9169E-7043-4F16-894D-FB0FEB947FC4 Q39870713-341EB56B-316C-4CE5-ACC3-B809874300C2 Q40254039-693C7008-F91F-470C-BA28-9EF658E04F41 Q40594199-8D78B15E-FDEC-410D-97CF-75B40D2260F0 Q41660559-3E29D68E-8DD3-4BBF-AE79-42A7FF29C323 Q46269946-027294DB-0ACA-481A-832C-2DD13DF79AB5 Q52970473-7CF3422B-0BC9-41F1-8B72-5698736682BD

P2860

Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials

http://www.wikidata.org/entity/Q57569239

description

article

@en

im Oktober 2002 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2002

@uk

name

Response to infliximab treatme ...... , prospective GCP-level trials

@en

Response to infliximab treatme ...... , prospective GCP-level trials

@nl

type

label

Response to infliximab treatme ...... , prospective GCP-level trials

@en

Response to infliximab treatme ...... , prospective GCP-level trials

@nl

prefLabel

Response to infliximab treatme ...... , prospective GCP-level trials

@en

Response to infliximab treatme ...... , prospective GCP-level trials

@nl

P1433

Q57569239-83437515-13C5-4F7F-9E23-E8A2F3EAD8FA

P1476

Q57569239-01F3AFE1-4932-49EB-8B81-A268B7B7231F

P2093

Q57569239-043E4DDA-6955-4433-B1D3-38DDE09760F4

Q57569239-43C52B7B-BB4C-493F-8D94-07C2CB4ABF53

Q57569239-46A9E0E6-B14B-4059-8C75-9C07FAB48D32

Q57569239-6BB84565-A7A9-4655-B780-63417EFE8AE2

Q57569239-6F4470BD-1DE6-4079-9A02-E37F60361593

Q57569239-8C923AA3-CB06-4F59-BDBC-81137966C98E

Q57569239-8DA60018-8093-4322-AFF4-D277343C7EDF

Q57569239-91A6F34B-DD97-403E-BD69-631A52298436

Q57569239-E3F02B5F-715D-44C6-8013-7D3CBDE2E821

P304

Q57569239-EDEEDF2B-A977-43FD-8BEC-E4CA86812F6D

P31

Q57569239-46D3D0BB-0A4C-4E53-9E4D-71630F97007D

P356

Q57569239-867E5FD5-B9BA-4BB1-B822-54C5E8CBEFB8

P433

Q57569239-5412E871-ABDA-4316-9777-94D9EB50FAEC

P478

Q57569239-FECFC3E1-435C-4C02-A777-34DAA3C8718F

P50

Q57569239-BBE922B7-F2B4-47A6-878F-D052DB73C7A8

P577

Q57569239-1E48A341-4FBE-4ACA-A399-60287625BEF5

P698

Q57569239-2C54F23A-BCD7-44FF-9082-43BADB485B72

P356

00008571-200210000-00002

P1433

Pharmacogenetics and Genomics

P1476

Response to infliximab treatme ...... , prospective GCP-level trials

@en

P2093

Allan Olson

http://www.w3.org/2001/XMLSchema#string

Peter J P Croucher

http://www.w3.org/2001/XMLSchema#string

Silvia Mascheretti

http://www.w3.org/2001/XMLSchema#string

Silvia Schubert

http://www.w3.org/2001/XMLSchema#string

Stefan Schreiber

http://www.w3.org/2001/XMLSchema#string

Susanna Nikolaus

http://www.w3.org/2001/XMLSchema#string

Tilo Andus

http://www.w3.org/2001/XMLSchema#string

Ulrich Robert Fölsch

http://www.w3.org/2001/XMLSchema#string

Weihang Bao

http://www.w3.org/2001/XMLSchema#string

P304

509-515

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/00008571-200210000-00002

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12360101

http://www.w3.org/2001/XMLSchema#string